Open access
Aug 2026
Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma
Background Although CD19 CAR-T cell therapy has improved outcomes in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), responses are variable and predictive biomarkers are lacking. The triglyceride glucose-body mass index (TyG-BMI)—a surrogate of insulin resistance—has shown prognostic value in solid tumors...
Ze-Lin Liu, Rui-Jun Yang, Jia-Wen Chen et al.
· Frontiers in Oncology · 0 citations